Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012; 205:1806-1810.

Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.

Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J. Virol. 2012; 86:10862-10865.

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.

Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012 Sep;86(18):9583-9. doi: 10.1128/JVI.00996-12. Epub 2012 Jul 3. PubMed PMID: 22761379; PubMed Central PMCID: PMC3446565.

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.

Bolton DL, Santra S., Swett C., Custers J., Song K., Balachandran H., Kozlowski PA., Letvin NL., Roederer M., Radosevic K. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine 2012; 30:5991-5998.

Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J. Virol. 2012; 86:625-629.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492(7427): 118-22.

Retroviral integrase proteins and HIV-1 DNA integration

Krishnan L, Engelman A. Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem 2012 Nov 30;287(49):40858-66. doi: 10.1074/jbc.R112.397760. Epub 2012 Oct 5. PubMed PMID: 23043109; PubMed Central PMCID: PMC3510789.

Anti-CD4 monoclonal antibody Ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope.

Pace CS, Fordyce MW, Franco D, Kao CY, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody Ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J. Acquir. Immune Defic. Syndr. 2013, 62(1): 1-9.

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc. Natl. Acad. Sci. USA 2012; 109:12111-12116.

Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Sajadi MM, Lewis GK, Seaman MS, Guan Y, Redfield RR, DeVico AL. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. J. Virol. 2012, 86(8): 5014-25.